

Sysmex's Corporate Profile

Kaoru Asano
President, Sysmex Corporation
June 2023

Index

- 1. About Sysmex Corporation
- 2. The Possibilities of Healthcare, and Initiatives toward the Future

About Sysmex Corporation

Corporate Philosophy for the Sysmex Group



Sysmex Way

Mission

Shaping the advancement of healthcare.

Value

We will continue to create unique and innovative values, and ensure *anshin* for individuals in society.

Mind

With passion and flexibility, we demonstrate our individual competence and unsurpassed teamwork.

Shared Values

To our Customers

Ensure *anshin* in our customers by the unmatched quality, advanced technology, mindful support and actions that reflect the needs of our customers.

We constantly seek to better understand what it is that our customers require so that we may generate new and more satisfactory solutions.

To our Employees

Ensure *anshin* that comes when each and every employee understands that their diversity and personhood is valued in a workplace where they may have opportunities to realize their potential. We value a spirit of independence and resilience and give employees opportunities for self-fulfillment and growth while rewarding them for their accomplishments.

To our Business Partners

Ensure anshin in a broad range of partnerships.

We strive to grow as a company in step with our partners-in-trade.

To our Shareholders

Ensure anshin through soundness and transparency in management policies.

We commit ourselves to an innovative yet consistent style of management for sustained growth and increased value for shareholders, promoting the proper disclosure of information and closer communication with them.

To Society

Ensure anshin when we resolve to be responsible members of society.


We carry out our business in strict compliance with the law and regulations meanwhile in adherence to the highest ethical standards; playing an active role addressing environmental and other issues facing our society today.

Anshin is a word at the core of the Sysmex corporate philosophy that embodies the essence of what we have been pursuing since our foundation, and has the following meanings:

- A state in which customers have no concerns about the safety and quality of our products and services.
- A state in which stakeholders can trust, be confident and reassured in our relationship, transactions, interaction, and all other matters.
- A state in which individuals in society can be in a calm state of mind with little or no anxiety about their own health, lives, or other matters.

Main Lines of Business






Sysmex is a group that supports people's health in the domain of in vitro diagnostics (IVD).

Sysmex's Business Model




■ Even after a customer purchases an instrument, we continue to provide the reagents,



Generates long-term, stable earnings that are relatively unaffected by economic fluctuations



Strength: A Robust, Integrated System Spanning R&D to Sales and Service



We communicate with customers through a robust, integrated system that enables us to respond quickly to changing environments and needs around the world.

Strength: Unique R&D Capabilities





Creating new technologies that will improve quality of life for patients around the world

Strength: A Global Network Structure



R&D

Quality assurance

Manufacturing and logistics

Sales and service



Affiliated companies **77**



R&D locations

24, in 9 countries



Manufacturing locations **22**, in **10** countries



Sales and service locations **62**, in **44** countries

As of March 31, 2023



Rollout of diagnostic instruments for malaria

A network spanning more than 190 countries and regions



Diagnosis and monitoring



Contribution to personalized medicine through genome testing

Enabling the development and stable supply of products and services that reflect the wishes of people in various countries and regions

Growth Trajectory





The Global Leader in Multiple Fields, Centered on Hematology



Sysmex's business domain

IVD

Testing of blood, urine and other samples

Global market share, by sales

No. 1



Hematology

Anemia, leukemia, thrombocytopenia, etc.



Hemostasis*

Hemophilia, myocardial infarction, stroke, etc.



Urinalysis

Urinary tract stones, renal disease, diabetes, etc.





Clinical chemistry

Diabetes, arteriosclerosis, liver and kidney dysfunction, etc.



Immunochemistry

Infectious diseases, thyroid diseases, hepatitis, atopic dermatitis, etc.



Gene testing


Breast cancer, lung cancer, colorectal cancer, etc.

Consolidated Earnings Forecast (Fiscal Year Ending March 31, 2024) and Dividend Forecast



 Consolidated earnings forecast (fiscal year ending March 31, 2024)

(Billions of yen)	Fiscal year ending March 31, 2024		Fiscal year ended March 31, 2023		
	Forecast	Ratio	Results	Ratio	% growth
Net sales	460.0	100.0%	410.5	100.0%	+12.1%
Operating profit	83.0	18.0%	73.6	17.9%	+12.6%



Dividend forecast for the fiscal year ending March 31, 2024


	Interim dividend	Year-end dividend	Total	Dividend ratio
Fiscal year ended March 31, 2023 (proposal)	¥40	¥42*	¥82	37.5%
Fiscal year ending March 31, 2024 (forecast)			¥84	33.8%

^{*} Including a commemorative dividend to celebrate 55th anniversary of establishment (¥2) The year-end dividend for the fiscal year ended March 31, 2023 is to be proposed at the 56th Ordinary General Meeting of Shareholders.

The Possibilities of Healthcare, and Initiatives toward the Future


Potential of the Healthcare Market







Product and Service Expansion










New products and services

Sysmex's New Long-Term Vision

"Together for a better healthcare journey"





Realizing a fulfilling and healthy society by reaching out to each and every one of the world's people

Contributing to the Testing of Alzheimer's Disease




Create simple blood-based method to diagnose Alzheimer's disease


Number of dementia patients continuing to increase

Now: Around 55.0 million +

2050: Around 130.0 million



60–70% of dementia cases are Alzheimer's disease



Reduce the physical, emotional, and financial burden on patients and provide opportunities to receive medical care In the future, contribute to prevention and early-stage detection

Taking on Challenges in New Business Domain: Surgery Support Robotics Business



Taking on a large market through innovation in surgical technology


New domain







Global market scale



Reference: Based on customer purchase prices
Sources: TechSci Research + Intuitive Surgical Annual Report 2021 (to 2025), Medicaroid's forecasts from 2030

18

In Closing...



We support figure skaters who are taking on the world!



Tatsuya Tsuboi Mai Mihara Kaori Sakamoto

Sponsoring the Thematic Project "Amplification of Lives" of Expo 2025, Osaka, Kansai, Japan



Please cheer them on!

Together for a better healthcare journey